CRL Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 22.12
- PEG ratio
- 0.12
- P/B
- 4.59
- P/S (TTM)
- 3.29
- EV/EBITDA
- 71.95
Profitability & growth
- ROE (TTM)
- -7.5%
- Operating margin
- 15.1%
- Revenue growth YoY
- -2.7%
- Dividend yield
- —
- Beta
- 1.41
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Charles River Laboratories
Company profileCharles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 251 BALLARDVALE STREET, WILMINGTON, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer